Want to see FR:ABNX full AI Analyst Report?
ABIONYX Pharma SA (ABNX) AI Stock Analysis
Top Page
ABIONYX Pharma SA
(Paris:ABNX)
The score is primarily held down by weak financial performance—persistent large losses, ongoing cash burn, and rising leverage with declining equity. Technical indicators are neutral-to-soft (negative MACD and price below longer-term averages), offering limited support. Valuation is also constrained by a negative P/E and no dividend yield data.
ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 70.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 148.35K
- Price to Earnings (P/E)
- -7.3
- Beta (1Y)
- -0.21
- Revenue Growth
- -10.38%
- EPS Growth
- -72.05%
- Country
- France
- Employees
- 49
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
ABIONYX Pharma SA Business Overview & Revenue Model
Company Description
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This...
How the Company Makes Money
ABIONYX Pharma SA primarily aims to generate revenue through the development and eventual commercialization (directly or via partners) of its drug candidates; however, specific, current revenue streams and amounts (e.g., product sales, licensing inco...
ABIONYX Pharma SA Financial Statement Overview
Summary
Financials reflect an early-stage biotech risk profile: revenues are small/volatile with sharply weaker gross margin in 2025 and very large operating losses (EBIT margin deeply negative). Cash flow remains consistently negative with ongoing free cash flow burn, while equity has eroded and leverage rose materially in 2025, reducing flexibility.
Income Statement
22NegativeBalance Sheet
45NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.88M | 4.06M | 4.60M | 4.64M | 5.25M | 675.00K |
| Gross Profit | 209.00K | 376.00K | 844.00K | 618.00K | 636.00K | 259.00K |
| EBITDA | -5.85M | -5.70M | -5.27M | -4.53M | -4.01M | -7.42M |
| Net Income | -8.06M | -5.55M | -4.40M | -3.52M | -4.21M | -5.82M |
Balance Sheet | ||||||
| Total Assets | 36.54M | 12.86M | 13.45M | 14.83M | 15.82M | 21.83M |
| Cash, Cash Equivalents and Short-Term Investments | 26.87M | 3.52M | 3.23M | 4.10M | 4.05M | 7.93M |
| Total Debt | 15.18M | 3.81M | 3.10M | 3.39M | 4.01M | 4.96M |
| Total Liabilities | 20.86M | 8.60M | 6.03M | 6.91M | 8.65M | 11.15M |
| Stockholders Equity | 15.68M | 4.26M | 7.42M | 7.92M | 7.17M | 10.68M |
Cash Flow | ||||||
| Free Cash Flow | -3.41M | -3.17M | -3.60M | -3.83M | -3.53M | -6.86M |
| Operating Cash Flow | -3.28M | -2.93M | -3.60M | -3.70M | -3.36M | -6.69M |
| Investing Cash Flow | -94.00K | -205.00K | -100.00K | -130.00K | -175.00K | 1.34M |
| Financing Cash Flow | 26.87M | 3.42M | 2.80M | 3.89M | -194.00K | 3.97M |
ABIONYX Pharma SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Negative. The current price of 1.62 is above the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.74, and below the 200-day MA of 2.63, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.26 is Neutral, neither overbought nor oversold. The STOCH value of 72.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABNX.
ABIONYX Pharma SA Peers Comparison
Overall Rating
FR:SIGHT46Neutral
FR:ALSEN45Neutral- FR:ABNX43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:SIGHT | 46Neutral | EUR 18.98M | -1.06 | 52.39% | ― | -610.31% | 43.88% |
| FR:ALSEN | 45Neutral | EUR 87.32M | -2.04 | -54.15% | ― | ― | 6.26% |
| FR:ABNX | 43Neutral | EUR 70.84M | -7.32 | -80.82% | ― | -10.38% | -72.05% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ABNX | ABIONYX Pharma SA | 1.62 | -2.39 | -59.63% | |
| FR:ALCOX | Nicox SA | 0.30 | -0.04 | -12.06% | |
| FR:SIGHT | GenSight Biologics | 0.08 | -0.05 | -38.89% | |
| FR:ALSEN | Sensorion SAS | 8.64 | -8.86 | -50.63% |
ABIONYX Pharma SA Corporate Events
ABIONYX Pharma Secures Full CER-001 Manufacturing Chain with AXPLORA Partnership
ABIONYX Pharma has completed an end-to-end manufacturing chain for its flagship biopharmaceutical CER-001 by signing a strategic purification partnership with CDMO AXPLORA, adding to existing industrial agreements with TEXCELL and OLON. The collabora...
ABIONYX Taps OLON for Scalable Manufacturing of Complex Biologic CER-001
ABIONYX Pharma has entered a strategic manufacturing partnership with global CDMO OLON to advance CER-001, a complex biologic based on full-length recombinant human apoA-I assembled into biomimetic HDL particles. The deal positions OLON to handle ups...
ABIONYX Pharma Updates Voting Rights as It Advances Sepsis-Focused Biotherapies
ABIONYX Pharma, a biopharmaceutical company focused on sepsis and critical care, develops apoA-I-based biologics and HDL carriers to address immune-inflammatory dysregulation in severe diseases where effective treatments are lacking. Backed by strong...
ABIONYX Pharma trims bond debt with share-backed repayment, keeps cash runway to 2028
ABIONYX Pharma has partially repaid €1.75 million of its bond financing with Fenja Capital II A/S, settling about 70% in cash and 30% through a reserved capital increase of €0.52 million via the issuance of 331,299 new shares. The new sha...
ABIONYX bolsters cash to €26.9m as losses deepen and sepsis strategy advances
ABIONYX Pharma reported first-half 2026 consolidated revenue of €1.9 million, generated entirely by its IRIS Pharma ophthalmology CRO unit, while its sepsis and LCAT deficiency programs remain pre-revenue and continue to supply bioproducts for...
ABIONYX Pharma Taps TEXCELL to Advance Viral Safety and Industrialization of CER-001
ABIONYX Pharma has entered a strategic partnership with TEXCELL, a division of ABL Diagnostics, to conduct viral safety and clearance studies for CER-001 as it prepares validation batches of its bioproduction process in France. The work is central to...
ABIONYX Pharma Updates Share Capital and Voting Rights Structure
ABIONYX Pharma reported that as of August 31, 2026, its outstanding share capital stood at 43,736,415 shares, corresponding to 55,932,492 gross voting rights and 55,705,013 net voting rights. The disclosure, made in line with AMF regulations on votin...
ABIONYX Pharma Posts €1.9 Million H1 Revenue and Extends Cash Runway to 2028
ABIONYX Pharma reported consolidated half-year revenue of €1.9 million at the end of June 2026, entirely driven by its ophthalmology CRO unit IRIS Pharma, with biotech operations recording no sales as the company continues supplying its bioprod...
ABIONYX Pharma Updates Share Capital and Voting Rights Structure
ABIONYX Pharma has disclosed its latest capital and voting rights structure, reporting 42,568,071 shares in circulation as of July 31, 2026, corresponding to 54,764,148 gross voting rights and 54,519,932 net voting rights. The publication distinguish...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026